India's drug regulator has banned the manufacture and sale of 35 fixed dose combinations (FDCs), citing concerns over patient ...

The Central Drugs Standard Control Organisation (CDSCO) has issued a stern directive to all State and Union Territory Drug ...

Continued treatment with AXS-05, a combination of dextromethorphan and bupropion, significantly reduces the risk for recurrence of Alzheimer’s disease–related agitation, phase 3 results show.

Background: Dextromethorphan (DM), the d-isomer of ... extrapolated to suggest that pregnant women should not use this drug because of the risk of birth defects. We conducted a controlled study ...

CDSCO asks States and UTs to act upon list of 35 FDCs declared as new drugs: Gireesh Babu, New Delhi Wednesday, April 16, 2025, 08:00 Hrs [IST] The Drugs Controller General of Ind ...

Agitated patients are often prescribed antipsychotic medications and sedatives off-label, but this can pose a risk to the ...

While humans have used opioids for their medicinal benefits, the drug has paved the path of both treatment and tragedy.

Drug repurposing, or finding new uses for existing medications, could potentially lower the cost of prescription drugs and medical expenses and accelerate the discovery of new treatments. In the ...

At the recent American Academy of Neurology (AAN) 2025 annual meeting, Axsome Therapeutics (Nasdaq: AXSM) presented promising data for AXS-05 (bupropion + dextromethorphan) in treating agitation ...

Time for spring cleaning! National Clean Out Your Medicine Cabinet Day falls annually on the third Friday of April — on April ...

NMDA antagonist dextromethorphan is an ingredient found ... However, it has a broader label as unlike J&J's drug it is indicated for use in previously-untreated MDD. Axsome's drug was given ...